Figure 3

Progression-free probability across post-diagnosis months for neuroblastoma RAS viral (v-RAS) oncogene homolog ( Nras ). Progression-free probability across post-diagnosis months for individuals with Low (25^th percentile) and High (75^th percentile) expression level of neuroblastoma RAS viral (v-RAS) oncogene homolog (Nras). With a high hazard estimate (HR = 3.93), the progression-free probability falls faster in individuals with high expression levels of Nras.